BEIJING (BLOOMBERG, AGENCE FRANCE-PRESSE, REUTERS) - China's recent approval of clinical trials of a Covid-19 vaccine administered by inhalation has cast the spotlight on alternative ways of delivery as the world continues to battle the pandemic.

Chinese company CanSino Biologics said in a filing on the Hong Kong stock exchange on March 23 that the inhalation vaccine candidate is jointly developed with the Beijing Institute of Biotechnology.